Sharma Mani's Form 4 filing
AstraZeneca PLC (AZN) · filed Sep 11, 2026
- Accession no.
- 0001104659-26-107055
- Filed
- Sep 11, 2026, 4:05 PM ET
- Trade date
- Aug 8-Sep 8, 2026
- Filing delay
- 34 daysLate
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions. Open-market purchases total $3.25K. It was filed 34 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Sharma ManiCIK 0002122411 | Officer (See Remarks) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Represents the automatic reinvestment of dividends accrued during the holding period of the Issuer's Restricted Share Plan, at a price of GBP118.96, which has been converted from British pounds sterling to United States dollars at a conversion rate of GBP1.0000 to $1.3498 on August 7, 2026 as published by the Board of Governors of the Federal Reserve System. The dividend equivalent units will vest and be released to the Officer at the end of the three year holding period.
Referenced by the price of 1 transaction in Table I.
- F2
Represents the acquisition of shares pursuant to the Issuer's Share Incentive Plan at a price of GBP120.26, which has been converted from British pounds sterling to United States dollars at a conversion rate of GBP1.0000 to $1.3521 on September 4, 2026 as published by the Board of Governors of the Federal Reserve System.
Referenced by the price of 1 transaction in Table I.
Remarks
SVP, Group Controller and Head of Global Finance Services